Jarchow-MacDonald Anna, Smith Michael, Seagar Amie-Louise, Russell Clark D, Claxton Pauline, Laurenson Ian F, Moncayo-Nieto Olga-Lucia
Scottish Mycobacteria Reference Laboratory, NHS Lothian Directorate of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Queen's Medical Research Institute, University of Edinburgh Centre for Inflammation Research, Edinburgh, United Kingdom.
Open Forum Infect Dis. 2022 Dec 12;10(1):ofac665. doi: 10.1093/ofid/ofac665. eCollection 2023 Jan.
An increase in infections with nontuberculous mycobacteria (NTM) has been noted globally, and their incidence has overtaken that of complex (MTBc) in many countries. Using data from a national reference laboratory, we aimed to determine if this trend could be observed in Scotland.
We undertook a retrospective review of all NTM isolates received by the Scottish Mycobacteria Reference Laboratory (SMRL) over 9 years from 2011 to 2019 inclusive. Clinical episodes were defined as per 2017 British Thoracic Society and 2020 American Thoracic Society/European Respiratory Society/European Society of Clinical Microbiology and Infectious Diseases/Infectious Diseases Society of America NTM guidelines. These rates were compared with Scottish tuberculosis rates over the same period.
Of 8552 NTM isolates from 4586 patients in 2011 to 2019, 7739 (90.5%) were considered clinically relevant. These represented 2409 episodes of NTM infection, with and complex being most common. A total of 1953 (81.1%) were pulmonary NTM infection episodes from 1470 patients and 456 extrapulmonary episodes from 370 patients. We estimated a rise in incidence from 3.4 to 6.5 per 100 000 person-years (2011-2019 inclusive), with an increase in NTM incidence over MTBc incidence in Scotland by 2017.
The incidence of NTM infection in Scotland has overtaken MTBc incidence. NTM infection leads to a costly health care burden, possibly as much as UK£1.47 million (US$ and €1.73 million) annually. We recommend standardization of isolate referral with clinical surveillance and implementation of agreed standards of care delivered through multidisciplinary teams. This would improve diagnosis and patient management as well as assessment of diagnostics and novel treatments through clinical trials.
全球范围内非结核分枝杆菌(NTM)感染有所增加,在许多国家其发病率已超过结核分枝杆菌复合群(MTBc)。利用一家国家参考实验室的数据,我们旨在确定在苏格兰是否也能观察到这一趋势。
我们对苏格兰分枝杆菌参考实验室(SMRL)在2011年至2019年(含)的9年时间里接收的所有NTM分离株进行了回顾性研究。临床病例按照2017年英国胸科学会以及2020年美国胸科学会/欧洲呼吸学会/欧洲临床微生物学和传染病学会/美国传染病学会的NTM指南进行定义。将这些发病率与同期苏格兰的结核病发病率进行比较。
在2011年至2019年期间,从4586名患者中分离出8552株NTM,其中7739株(90.5%)被认为具有临床相关性。这些代表了2409例NTM感染病例,其中 和 复合群最为常见。共有1953例(81.1%)是来自1470名患者的肺部NTM感染病例,以及来自370名患者的456例肺外感染病例。我们估计发病率从每10万人年3.4例上升至6.5例(2011年至2019年,含),到2017年苏格兰NTM的发病率超过了MTBc的发病率。
苏格兰NTM感染的发病率已超过MTBc的发病率。NTM感染导致高昂的医疗负担,每年可能高达147万英镑(210万美元和173万欧元)。我们建议规范分离株转诊并进行临床监测,通过多学科团队实施商定的护理标准。这将改善诊断和患者管理,以及通过临床试验对诊断方法和新疗法进行评估。